Free Trial

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Immunocore logo with Medical background

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $58.89.

Several equities analysts have commented on IMCR shares. HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Oppenheimer raised their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a research report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target on the stock. Wall Street Zen raised Immunocore from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price target on shares of Immunocore in a research report on Thursday, April 10th.

Get Our Latest Stock Analysis on IMCR

Institutional Trading of Immunocore

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after purchasing an additional 420 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Immunocore by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company's stock worth $1,996,000 after purchasing an additional 735 shares during the period. GF Fund Management CO. LTD. bought a new position in Immunocore during the fourth quarter worth $25,000. NEOS Investment Management LLC raised its stake in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after buying an additional 1,102 shares during the last quarter. Finally, Assetmark Inc. raised its stake in Immunocore by 4.8% during the first quarter. Assetmark Inc. now owns 33,710 shares of the company's stock worth $1,000,000 after buying an additional 1,539 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Trading Down 2.2%

Immunocore stock traded down $0.78 during midday trading on Thursday, reaching $35.27. The stock had a trading volume of 127,201 shares, compared to its average volume of 254,490. The firm's fifty day simple moving average is $33.97 and its two-hundred day simple moving average is $30.99. Immunocore has a twelve month low of $23.15 and a twelve month high of $40.88. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.36 and a quick ratio of 6.31. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -82.02 and a beta of 0.77.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The business had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same period in the prior year, the business posted ($0.49) earnings per share. Immunocore's revenue for the quarter was up 33.6% compared to the same quarter last year. Equities analysts anticipate that Immunocore will post -0.94 EPS for the current fiscal year.

Immunocore Company Profile

(Get Free Report

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Recommended Stories

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Should You Invest $1,000 in Immunocore Right Now?

Before you consider Immunocore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.

While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines